Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.

Her PhD work led to the deorphanization of ChemR23, a G protein-coupled receptor specifically expressed on mononuclear phagocytes, and to the identification of chemerin, a new immune player with ...

Urcosimod, previously known as OK-101, is a lipid conjugated chemerin peptide agonist targeting the ChemR23 receptor, which is involved in the body’s inflammatory response and pain perception. The ...

Urcosimod, previously known as OK-101, is a lipid conjugated chemerin peptide agonist targeting the ChemR23 receptor, which is involved in the body’s inflammatory response and pain perception.

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune cells of the eye responsible for the inflammatory response. Okyo Pharma has ...